SELLAS FY25 Net Loss Narrows; Approaching Final Analysis Of The Phase 3 REGAL Trial For GPS In AML

AI Briefing

• – SELLAS Life Sciences Group, Inc. reported a narrower net loss for FY25, the company is nearing the completion of the Phase 3 REGAL trial for its GPS treatment in AML, and will finalize its analysis of the trial's results in the coming months.